Beckman Coulter Life Sciences, Indianapolis, has acquired Labcyte, a privately held acoustic liquid handling company based in San Jose, Calif.
Jonathan Pratt, Beckman Coulter Life Sciences.
Labcyte is best known for its Echo acoustic droplet ejection technology, which uses sound waves to transfer tiny amounts of liquid quickly and accurately. The technology enables walkaway convenience and integration capabilities, along with cost-effective laboratory workflows in applications such as drug discovery and genomics.
“Labcyte’s unique product portfolio complements our existing liquid handling and laboratory automation business,” says Jonathan Pratt, president of Beckman Coulter Life Sciences. “It provides new opportunities to develop and enhance time-saving solutions for customer workflows.”
Richard Ellson, LabCyte.
“It has been an exciting journey—from developing acoustic liquid-dispensing technology in a garage to establishing a global presence—and now to be joining forces with a life sciences technology leader,” adds Richard Ellson, a founder and chief technology officer at Labcyte. “Acoustic liquid handling is quickly becoming the backbone for high-throughput, automated workflows, and we look forward to accelerating growth and innovation as part of the Beckman Coulter Life Sciences team.”
Labcyte will transition into Beckman Coulter Life Sciences under the larger Danaher Life Sciences group of companies, which generates approximately $6.5 billion in annual revenue.
For further information, visit Labcyte.
Featured image: The Echo 550 liquid handler by LabCyte.
